New combination improves radiation therapy outcomes in patients with locally advanced and borderline resectable pancreatic cancer
First author Cullen Taniguchi, M.D., Ph.D., passed away suddenly before the final publication of this study. A talented physician-scientist motivated by the impact of cancer on his own family, Taniguchi was committed to improving treatment options and outcomes for patients with gastrointestinal cancers as well as mentoring aspiring physicians and scientists.
“Dr. Taniguchi was a pioneer, committed to not accepting the low...
mRNA delivered by extracellular vesicles induces immunotherapy response in glioblastoma
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to...
MD Anderson Research Highlights: ASTRO 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Research identifies new potential hurdle for nano-based therapies
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.
The researchers found age-related differences are due to how effectively the liver filters the bloodstream. Younger livers are more efficient at this...
Study brings new understanding of multiple myeloma evolution
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma...
Pan-cancer T cell atlas reveals new details of tumor microenvironment
A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper...
AACR: Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
ABSTRACTS: CT016, CT018
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings...
AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers
ABSTRACT: CT006
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced...
New cell death mechanism could offer novel cancer treatment strategies
A study from researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Cell Biology, details a previously...
Three MD Anderson researchers elected AAAS Fellows
Three researchers at The University of Texas MD Anderson Cancer Center have been named fellows of the American Association for the Advancement...
Scientists develop novel mRNA delivery method using extracellular vesicles
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA...
Novel T cell receptor therapy shows early anti-tumor activity
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved...